PHARMACY

Lupin’s generic Onfi gets FDA approval

BY Sandra Levy

Lupin has received the Food and Drug Administration’s blessing for Clobazam oral suspension, 2.5 mg/mL.

The product is a generic version of Lundbeck’s Onfi oral suspension, 2.5 mg/mL.

It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age or older.

Clobazam oral suspension, 2.5 mg/mL had a market value of approximately $260.2 million, according to IQVIA September 2018 data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

What area is your company focused most on in 2019?
  • Add your answer